Cargando…
Safety and Activity of the Combination of Ceritinib and Dasatinib in Osteosarcoma
Osteosarcoma (OS) is the second most common cause of cancer-related death in pediatric patients. The insulin-like growth factor (IGF) pathway plays a relevant role in the biology of OS but no IGF targeted therapies have been successful as monotherapy so far. Here, we tested the effect of three IGF s...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225940/ https://www.ncbi.nlm.nih.gov/pubmed/32224911 http://dx.doi.org/10.3390/cancers12040793 |
_version_ | 1783534170448855040 |
---|---|
author | Beck, Olaf Paret, Claudia Russo, Alexandra Burhenne, Jürgen Fresnais, Margaux Steimel, Kevin Seidmann, Larissa Wagner, Daniel-Christoph Vewinger, Nadine Lehmann, Nadine Sprang, Maximilian Backes, Nora Roth, Lea Neu, Marie Astrid Wingerter, Arthur Henninger, Nicole El Malki, Khalifa Otto, Henrike Alt, Francesca Desuki, Alexander Kindler, Thomas Faber, Joerg |
author_facet | Beck, Olaf Paret, Claudia Russo, Alexandra Burhenne, Jürgen Fresnais, Margaux Steimel, Kevin Seidmann, Larissa Wagner, Daniel-Christoph Vewinger, Nadine Lehmann, Nadine Sprang, Maximilian Backes, Nora Roth, Lea Neu, Marie Astrid Wingerter, Arthur Henninger, Nicole El Malki, Khalifa Otto, Henrike Alt, Francesca Desuki, Alexander Kindler, Thomas Faber, Joerg |
author_sort | Beck, Olaf |
collection | PubMed |
description | Osteosarcoma (OS) is the second most common cause of cancer-related death in pediatric patients. The insulin-like growth factor (IGF) pathway plays a relevant role in the biology of OS but no IGF targeted therapies have been successful as monotherapy so far. Here, we tested the effect of three IGF specific inhibitors and tested ceritinib as an off-target inhibitor, alone or in combination with dasatinib, on the proliferation of seven primary OS cells. Picropodophyllin, particularly in combination with dasatinib and the combination ceritinib/dasatinib were effective in abrogating the proliferation. The ceritinib/dasatinib combination was applied to the primary cells of a 16-year-old girl with a long history of lung metastases, and was more effective than cabozantinib and olaparib. Therefore, the combination was used to treat the patient. The treatment was well tolerated, with toxicity limited to skin rush and diarrhea. A histopathological evaluation of the tumor after three months of therapy indicated regions of high necrosis and extensive infiltration of macrophages. The extension of the necrosis was proportional to the concentration of dasatinib and ceritinib in the area, as analysed by an ultra performance liquid chromatography–tandem mass spectrometer (UPLC-MS/MS). After the cessation of the therapy, radiological analysis indicated a massive growth of the patient’s liver metastases. In conclusion, these data indicate that the combination of ceritinib/dasatinib is safe and may be used to develop new therapy protocols. |
format | Online Article Text |
id | pubmed-7225940 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-72259402020-05-18 Safety and Activity of the Combination of Ceritinib and Dasatinib in Osteosarcoma Beck, Olaf Paret, Claudia Russo, Alexandra Burhenne, Jürgen Fresnais, Margaux Steimel, Kevin Seidmann, Larissa Wagner, Daniel-Christoph Vewinger, Nadine Lehmann, Nadine Sprang, Maximilian Backes, Nora Roth, Lea Neu, Marie Astrid Wingerter, Arthur Henninger, Nicole El Malki, Khalifa Otto, Henrike Alt, Francesca Desuki, Alexander Kindler, Thomas Faber, Joerg Cancers (Basel) Article Osteosarcoma (OS) is the second most common cause of cancer-related death in pediatric patients. The insulin-like growth factor (IGF) pathway plays a relevant role in the biology of OS but no IGF targeted therapies have been successful as monotherapy so far. Here, we tested the effect of three IGF specific inhibitors and tested ceritinib as an off-target inhibitor, alone or in combination with dasatinib, on the proliferation of seven primary OS cells. Picropodophyllin, particularly in combination with dasatinib and the combination ceritinib/dasatinib were effective in abrogating the proliferation. The ceritinib/dasatinib combination was applied to the primary cells of a 16-year-old girl with a long history of lung metastases, and was more effective than cabozantinib and olaparib. Therefore, the combination was used to treat the patient. The treatment was well tolerated, with toxicity limited to skin rush and diarrhea. A histopathological evaluation of the tumor after three months of therapy indicated regions of high necrosis and extensive infiltration of macrophages. The extension of the necrosis was proportional to the concentration of dasatinib and ceritinib in the area, as analysed by an ultra performance liquid chromatography–tandem mass spectrometer (UPLC-MS/MS). After the cessation of the therapy, radiological analysis indicated a massive growth of the patient’s liver metastases. In conclusion, these data indicate that the combination of ceritinib/dasatinib is safe and may be used to develop new therapy protocols. MDPI 2020-03-26 /pmc/articles/PMC7225940/ /pubmed/32224911 http://dx.doi.org/10.3390/cancers12040793 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Beck, Olaf Paret, Claudia Russo, Alexandra Burhenne, Jürgen Fresnais, Margaux Steimel, Kevin Seidmann, Larissa Wagner, Daniel-Christoph Vewinger, Nadine Lehmann, Nadine Sprang, Maximilian Backes, Nora Roth, Lea Neu, Marie Astrid Wingerter, Arthur Henninger, Nicole El Malki, Khalifa Otto, Henrike Alt, Francesca Desuki, Alexander Kindler, Thomas Faber, Joerg Safety and Activity of the Combination of Ceritinib and Dasatinib in Osteosarcoma |
title | Safety and Activity of the Combination of Ceritinib and Dasatinib in Osteosarcoma |
title_full | Safety and Activity of the Combination of Ceritinib and Dasatinib in Osteosarcoma |
title_fullStr | Safety and Activity of the Combination of Ceritinib and Dasatinib in Osteosarcoma |
title_full_unstemmed | Safety and Activity of the Combination of Ceritinib and Dasatinib in Osteosarcoma |
title_short | Safety and Activity of the Combination of Ceritinib and Dasatinib in Osteosarcoma |
title_sort | safety and activity of the combination of ceritinib and dasatinib in osteosarcoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225940/ https://www.ncbi.nlm.nih.gov/pubmed/32224911 http://dx.doi.org/10.3390/cancers12040793 |
work_keys_str_mv | AT beckolaf safetyandactivityofthecombinationofceritinibanddasatinibinosteosarcoma AT paretclaudia safetyandactivityofthecombinationofceritinibanddasatinibinosteosarcoma AT russoalexandra safetyandactivityofthecombinationofceritinibanddasatinibinosteosarcoma AT burhennejurgen safetyandactivityofthecombinationofceritinibanddasatinibinosteosarcoma AT fresnaismargaux safetyandactivityofthecombinationofceritinibanddasatinibinosteosarcoma AT steimelkevin safetyandactivityofthecombinationofceritinibanddasatinibinosteosarcoma AT seidmannlarissa safetyandactivityofthecombinationofceritinibanddasatinibinosteosarcoma AT wagnerdanielchristoph safetyandactivityofthecombinationofceritinibanddasatinibinosteosarcoma AT vewingernadine safetyandactivityofthecombinationofceritinibanddasatinibinosteosarcoma AT lehmannnadine safetyandactivityofthecombinationofceritinibanddasatinibinosteosarcoma AT sprangmaximilian safetyandactivityofthecombinationofceritinibanddasatinibinosteosarcoma AT backesnora safetyandactivityofthecombinationofceritinibanddasatinibinosteosarcoma AT rothlea safetyandactivityofthecombinationofceritinibanddasatinibinosteosarcoma AT neumarieastrid safetyandactivityofthecombinationofceritinibanddasatinibinosteosarcoma AT wingerterarthur safetyandactivityofthecombinationofceritinibanddasatinibinosteosarcoma AT henningernicole safetyandactivityofthecombinationofceritinibanddasatinibinosteosarcoma AT elmalkikhalifa safetyandactivityofthecombinationofceritinibanddasatinibinosteosarcoma AT ottohenrike safetyandactivityofthecombinationofceritinibanddasatinibinosteosarcoma AT altfrancesca safetyandactivityofthecombinationofceritinibanddasatinibinosteosarcoma AT desukialexander safetyandactivityofthecombinationofceritinibanddasatinibinosteosarcoma AT kindlerthomas safetyandactivityofthecombinationofceritinibanddasatinibinosteosarcoma AT faberjoerg safetyandactivityofthecombinationofceritinibanddasatinibinosteosarcoma |